The US Food and Drug Administration (FDA) has designated MAIA Biotechnology’s immunotherapy THIO for the treatment of paediatric-type diffuse high-grade gliomas (PDHGG) as a drug for a rare paediatric disease. “THIO is a versatile anti-cancer agent that has demonstrated positive results in multiple difficult to treat cancer types, including paediatric… Read More
Nathan Yee, Senior Director of CMC Portfolio Strategy at Tune Therapeutics, and Lucas Thompson, Senior Director of Research at Tune Therapeutics, discuss the opportunities and challenges in cell therapy. Cell therapy is a transformative medical approach that harnesses living cells as therapeutic agents and has demonstrated the potential to address… Read More
Final draft guidance from the UK’s National Institute for Health and Care Excellence (NICE) recommends the use of elacestrant, the first tailored treatment for locally advanced and metastatic breast cancer with mutations in the ESR1 gene. Specifically, the drug will be available on the NHS to treat post-menopausal women, and… Read More
Ottimo Pharma has completed a Series A financing round of over $140 million. The financing will accelerate the lead asset, Jankistomig, a first-in-class PD1/VEGFR2 bifunctional antibody for multiple solid tumour indications, in both IV and SC forms as well as a pipeline of follow-on bifunctional assets. The round was led… Read More
Recursion has reported initial monotherapy dose-escalation data from the Phase I/II study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumours. These results were presented after market close at an AACR Special Conference in Cancer Research. “Cell cycle dysregulation and transcriptional ‘addiction’ are both hallmarks of many aggressive… Read More
According to new data, a cyclin-dependent kinase 2 (CDK2)-directed molecular glue degrader (MGD) drove deep tumour regression in preclinical models of HR-positive/HER2-negative breast cancer. Monte Rosa Therapeutics will present the preclinical data at the 2024 San Antonio Breast Cancer Symposium, held 10-13 December in San Antonio, Texas. Read More
Synthekine has announced positive initial results from a Phase I study of SYNCAR-001 + STK-009 for the treatment of relapsed or refractory CD19+ haematologic malignancies. In the results presented from eight patients treated in the dose escalation portion of the study with a fixed SYNCAR-001 infusion of… Read More
Cancer Research Horizons is partnering with Diamond Light Source, the UK’s national synchrotron, to build a world-leading fragment-based drug discovery programme. Diamond Light Source accelerates electrons to near light speed, producing bright light that is directed into research instruments known as beamlines. Cancer Research Horizons and its drug discovery site… Read More
Gold-based drugs can slow tumour growth in animals by 82% and target cancers more selectively than standard chemotherapy drugs, according to new research. The study published in the European Journal of Medicinal Chemistry reveals a new gold-based compound that’s 27 times… Read More
A new chimeric antigen receptor T cell (CAR-T) therapy has delivered highly promising results in treating patients with relapsed/refractory B-cell acute lymphoblastic leukaemia (r/r B-ALL). The FELIX clinical trial was led by researchers at University College London (UCL) and UCLH and sponsored by UCL spin-out Autolus Therapeutics. Read More
A new precision medicine approach that combines genetic and functional profiling could predict how glioblastoma will respond to therapy. A new study from scientists at the UCLA Health Jonsson Comprehensive Cancer Center helps explain why glioblastoma becomes resistant to treatment and introduces a new approach that paves… Read More
Megan Thomas explores the innovation and opportunity for cancer vaccines with Dr Alexander Zehnder, CEO of CureVac, and Dr Chris Haqq, Chief Medical Officer of Elicio Therapeutics. It could be argued that Covid-19 gave us a boost to start making headway in cancer vaccines. Between the acceleration of mRNA vaccine… Read More
Researchers have identified 330 potential cancer-driving genes, 74 of which are newly associated with cancer. The findings highlight the potential to develop new, more targeted treatment options and provide hope that existing cancer treatments, such as PARP inhibitors, could be extended to thousands more patients. Read More
Dr Jill O’Donnell Tormey, CEO and Director of Scientific Affairs at the Cancer Research Institute, US, discusses the future of cancer research with DDW's Megan Thomas. Innovation & opportunity Reflecting on innovation and opportunity in global cancer research, Dr Jill O’Donnell-Tormey recognises modalities like cell therapies, bispecifics, antibody drug conjugates… Read More
World Pancreatic Cancer Day takes place on 21 November to raise awareness about pancreatic cancer, support patients and their families, and advocate for increased research and early detection of this deadly disease. iOnctura’s Chief Medical Officer Michael Lahn discusses how we can fight the disease by breaking the defensive wall surrounding… Read More
Researchers have identified a key weakness in acute myeloid leukaemia (AML), offering a promising new strategy to delay the progression of this aggressive blood cancer. The discovery focuses on disrupting the function of the nucleosome-remodelling factor (NURF) complex, which cancer cells, including leukaemia cells, rely on… Read More
